The objective o f the present study was to define the role o f chem otherapy, in the form o f the EP regim en, consisting o f epirubicin (E) and cisplatin (P) in addition to irradiation in com bination with 5-fluorouracil (5-FU) for treatm ent o f pancreatic cancer. 53 eligible patients with histologically or cytologically proven locally advanced pancreatic cancer were treated with three cycles o f E 60 mg/m2 (if this dose w as well tolerated then the dose o f E was increased by 10 m g/m 2 in the next cycle; 80 mg/m2 was the m axim um dose for the following cycles) and P 100 m g/m 2 once every 3 weeks, follow ed after 4 weeks by a split course o f irradiation o f 40 Gy with 5-FU 500 m g/m 2 on each o f the first 3 days o f each 20 Gy treatm ent segm ent. T his was followed by another three cycles o f EP in patients w ho achieved stable disease (SD ) or a better response after the first three cycles. The treatm ent given w ith standard anti-em etics w as m oderately tolerated. The chem otherapy related toxicity consisted m ain ly o f myelosuppression and the chem oradiotherapy related toxicity o f gastrointestinal side-effects. H ow ever, due to the long duration o f treatm ent which made the whole treatm ent difficult to endure, only 18/53 (34%) actually com pleted the full treatm ent regim en. R esponses were evaluated after the first three cycles and 4 weeks after the com pletion o f the treatm ent by serial CT-scans using standard criteria* The results in 53 evaluable patients after the first three cycles o f EP were as follows: 1 patient achieved a clinical com plete response (CR), 7 a partial response (PR) (CR + PR: 15%; 95% confidence interval (Cl): 11-33%), 36 patients (68%) had stable disease (SD) and 6 patients progressive disease (P D ). There was 1 early P D , 1 toxic death and 1 patient could not b e evaluated. The response at th e end o f the treatm ent was 3 CR, 11 PR (CR + PR: 14/53 (26%); 95% Cl: 15-40%), 30 SD and 6 P D . The m ed ian time to progression was 8.9 m onths and the m edian duration o f response 13.1 m onths. The m ed ia n survival o f all treated patients was 10.8 m onths (range 7 days to 41.5 m onths), o f responders 15.1 m onths and, o f the patients with SD 10.3 m onths. These results are comparable to other com bined modality regim ens reported in the literature for locally advanced disease. The addition o f the system ic treatm ent w ith E and P offers no additional advantage to com bined m odality treatm ent alone. C opyright © 1996 Published by E lsevier Science Ltd Key words: locally advanced pancreatic cancer, com bined m odality treatm ent
INTRODUCTION
T he i n c i d e n c e of adenocarcinom a o f the pancreas has steadily increased over the past four decades [1] . Despite trem endous efforts in early diagnosis and therapy the prognosis is still Correspondence to D.J.Th, Wagener. Received 27 Mar. 1995; revised 1 Jan. 1996^ accepted 9 Feb. 1996. dismal. T h e percentage of surgically resectable patients is less than 2 0 %j and of those resected the m edian survival is only 9-15 m onths [23 3] while 5-year survival rates are less than 5% [4, 5] .
Approximately 40% of patients with pancreatic cancer pre sent with locally advanced disease [6] . This stage has been defined as unresectable disease due to regional lym ph node involvement and/or encasement of m ajor b lo o d vessels, but in n Com bined M odality T reatm en t of Pancreatic Cancer 1311 without evidence of hepatic or other distant métastasés. T o be staged as locally advanced* it should be possible to encompass the tu m o u r in a moderately sized upper gastrointestinal radi ation target volume. Currently accepted management involves the use of combined modality treatm ent with 5-fluor our a cil (5-FU) and radiation therapy [7] .
Chem otherapy is poorly active [8] , but previous studies from our E O R T C group have reported an objective significant response after epirubicin treatment [9] and cisplatin adm inis tration [10] .
T h e objective of the present study was to define the role of chemotherapy* in the form of the E P regimen* consisting o f epirubicin (E) and cisplatin (P) in addition to irradiation in com bination with 5-FU for treatm ent of pancreatic cancer.
PATIENTS AND METHODS
All patients entered into this trial had histologically or cytologically proven ductal adenocarcinoma of the pancreas. Inclusion criteria included the following: inoperable disease due to ingrowth in surrounding tissue or positive regional lymph nodes; no distant metastases on chest X-ray-anteriorposterior and lateral-and on the CT-scan of the whole abdo men; age less than 71 years; W H O performance status ^2 ; kidney and liver function tests normal; WBC ^4 x l 0 9/l* platelet count s i 00 x 109/1; all regional disease encompassed within a 400 cm 2 radiation therapy field. Informed consent was required. Criteria for exclusion were: prior chemotherapy or radiotherapy* active infection* brain or leptomeningeal disease* concom itant other malignant disease and overt car diac disease.
Statistical considerations
T h e first endpoint analysed was response to treatm ent. Survival and side-effects were also described.
T h e sample size calculation was based on the two-stage G e h a n 's design aiming to include 9 patients and then includ ing additional patients according to the number of responses observed in the first stage. This guarantees that the probability of an active treatm ent (real response rate ^30% ) exhibiting no responses in the first 9 patients (that is, false negative result) is 0.05 and allows the effectiveness of the treatm ent regim en to be estimated with a standard error of 10% [11] .
Survival curves and time to progression curves were esti m ated using the K aplan-M eier technique [12] .
Treatm ent
T h e chem otherapy was given according to the following schedule: E 60 m g/m 2 i.v, on day 1. If this dose was well tolerated, then the dose of E was increased by 10 m g/m 2 in the following cycles to 80 mg/m2 as the maximum dose. P 100 m g/m 2 diluted in 1 litre normal saline was adm inistered over a 4-h period with adequate pre-and posthydration. T h e cycle was repeated every 21 days. T h e drug dose was modified for subsequent courses according to the degree of haematological toxicity (Table 1) .
If the treatm ent had to be postponed for more than 4 weeks* the response to treatm ent was evaluated and the patient went off study. T h e dose of E was reduced by 50% in the presence of a bilirubin level of 35-50 mmol/1; no epirubicin was given if this level reached > 5 0 mmol/1.
After three cycles of EP* the patients were given irradiation therapy as described by the Gastrointestinal T u m o r Study [7] consisting of 40 Gy (split course) in com bination with 5-F U (500 m g/m 2) given as a bolus injection immediately prior to radiotherapy on days 1-3 of the two irradiation periods of 2 weeks each* with an interval of 2 weeks. After the irradiation* another three cycles o f E P were given if after three cycles stable disease (SD) or a better response was achieved.
T h e patients were evaluated for response after three cycles of chemotherapy and 4 weeks after six cycles. T h e response was assessed by computerised tom ography (C T). T he response was defined according to W H O guidelines for nonmeasurable disease [13] . A complete response (CR) was there fore defined as the complete disappearance of all known disease. A partial response (PR) was defined as an estimated decrease in tum our size of ^5 0 % , and no change (N C) was defined as no significant change. T h e latter included SD* an estimated decrease in tum our size ^50% * and lesions with an estimated size increase of < 25% . Disease progression (PD) was defined as the appearance of a new lesion n o t previously identified or an estim ated increase of 2=25% in the size of existent lesions. A confirmation after 4 weeks was required in case of C R or PR. T he duration of response and of survival were m easured from the start of chem otherapy. Toxicity was assessed using a 0 -4 grading system according to the W H O [13] , The R T O G /E O R T C Late Radiation M orbidity Scoring scheme was also used for the small/large intestine* liver* kid ney* spinal cord and skin.
RESULTS
Between O ctober 1987 and January 1992* 61 patients with locally advanced disease were registered into the trial. Six patients did not fulfil the inclusion criteria: no measurable lesions for 2 patients* 1 had an inadequate histology, 1 liver metastases* 1 had ascites and 1 also had breast cancer and was treated with C M F. 2 other patients* although eligible* were excluded from the analysis because they experienced digestive haem orrhage before the treatm ent could start. Consequently, the results are based on the 53 eligible patients for whom the treatm ent started. T h e patient characteristics are given in Table 2 . All 53 patients had histological confirmation of adenocarcinom a of the pancreas.
O f the 53 eligible patients, 49 received th e required initial three cycles of chemotherapy. O f these 49 patients* 8 had progression and therefore were not given any further treatm ent and 1 patient refused further treatm ent due to persistent nausea and vomiting. In addition to the rem aining 40 patients* 1 m ore patient* who received only two cycles of chemotherapy* received radiotherapy because he was considered unfit for further chemotherapy. O ut of these 41 patients who received radiotherapy* 37 com pleted the radiotherapy split course while the otiier 4 patients received only the first part. 2 patients could not tolerate any m ore treatm ent, 1 suffered a digestive haem orrhage and jaundice and the other had progressive disease. A m ong the 37 patients who com pleted the split D J .T h . W agener et a l course, 24 patients received further chemotherapy and 13 patients did not receive any more chemotherapy: 8 patients had progression* 3 refused further treatment, and treatment was stopped for 2 patients due to toxicity, Treatment was stopped for 1 patient due to excessive toxicity after the fourth cycle of chemotherapy. 5 more patients had only five cycles: 2 due to toxicity, 1 refused further treatment, 1 had a very poor digestive tolerance and 1 was lost to follow-up after the fifth cycle. 18 patients (34%) completed the additional three cycles o f chemotherapy. The response after the first three cycles of chemotherapy was 1 CR, 7 PR (CR + PR; 8/53, 15%; 95% Cl: 7-28% ), 36 SD and 6 PD ( Table 3) system which indicates a 3 if anti-emetics are given prophylactically. In fact, most patients received anti-emetics by which the treatment was tolerable. The split course irradiation in combination with 5-FU was also generally well tolerated.
DISCUSSION
Treatment of locally advanced pancreatic cancer is at best palliative. The best approach seems to be a combination of systemic treatment with irradiation [8] . However* only one randomised trial has proven this [7] . According to data from the literature, a median survival between 8.4 and 14 months can be expected with the combined approach, whereas the median survival for untreated patients with locally advanced disease is between 3-5 months [8] .
The aim o f this study was to investigate the role of the addition of systemic treatment in the form of E and P to the known local treatment consisting of irradiation in combination with 5-fluorouracil. The treatment was moderately tolerated. The chemotherapy-related toxicity consisted mainly of myelosuppression and the chemoradiotherapy-related toxicity of gastrointestinal side-effects. However, although according to WHO criteria the toxicity was mild, the long duration o f the treatment period makes the complete treatment difficult to endure.
T he results obtained in this study (median survival 10.8 m onths) are not superior to the data obtained with the com bined modality treatment published in the literature [7] . Therefore, we conclude that the addition o f the sys temic treatment with E and P seems to offer no additional advantage and cannot be recommended, although simpler regimens of chemotherapy followed by irradiation (± chemotherapy) might be worth assessing, particularly because o f the potential advantage of identifying the initial chemotherapy responders.
T o place the results of this trial in proper perspective, it should be noted that this was a multicentre study and that there was no upper limit to the size of the tumour in patients treated in this study. Patients with tumours as great as 11 cm in diameter were included in the trial. It is likely that patients with such large tumours have distant metastases.
The combined modality approach is only worthwhile for localised disease. Therefore, the staging procedure in locally advanced disease should include a laparoscopic evaluation. Nearly half the patients with presumed resectable localised disease appear to have small but visible abdominal metastases during laparoscopy [14, 15] . In the non-resectable cases, this is probably even more.
From an experimental and theoretical point of view* it is of importance for future trials not to interrupt the cytostatic treatment period.
Another reason not to divide the treatment period is that only about half the patients could be treated according to the planned treatment schedule and could receive chemotherapy after the irradiation. For most patients, the whole schedule is too difficult to endure and in addition, because m ost of the responses were documented after the first three cycles, it remains questionable whether the postirradiation courses of chemotherapy are of any use.
To improve the results of treatment of pancreatic cancer, it is of great importance to have more effective chemotherapy schedules. N ew drugs or better combination treatments are urgently needed.
An important question which should also be answered in the near future is: what is the best chemo-irradiation regi men? From the radiobiological point o f view, the split course irradiation is now considered outdated, but so far no irradiation schedule has been demonstrated to be superior.
